Luxembourg The recently appointed managing director of Pfizer Luxembourg discusses the current footprint of the company in the country; how every affiliate within the group counts; market access procedures; and the role of Luxembourg within the life sciences and healthcare sector. Since September 2016, you have been managing director of Pfizer…
Switzerland As the home market, Switzerland and Roche’s Swiss pharma operations play an important and pioneering role within Roche’s global organization, with early patient access to innovation and new commercial models taking place in the country. The working title of the Healthcare & Life Science Review Switzerland is “A Leader Among…
Pfizer Rodrigo Puga, the recently appointed general manager of Pfizer Mexico, documents his strategic priorities to further strengthen the company’s performance in Mexico and consolidate Pfizer’s leadership within the Mexican market and the overall healthcare eco-system of the country. You were appointed country manager of Pfizer Mexico in June 2016, while…
Switzerland Heike Behn, reveals how her number one priority at Nordic Pharma Switzerland, the group’s’newest affiliate, is to develop their rheumatology business, building on their gynecology platform; how the speed with which they can approach the customer is a major competitive advantage for the company; and how Switzerland´s approval process, when…
Mexico Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims to be recognized as a strategic sector by both the Ministries of Health and Economy. He highlights Novartis Mexico’s leadership in…
Singapore With Amgen having recently reacquired the sales rights to three of its drugs, the company’s GM in Singapore and Malaysia, Raphael Ho, explains the rationale behind Amgen’s recent entry in Singapore and his experience in setting up the affiliate, while also expounding upon the unique value of Amgen products in…
Switzerland Carolin Hillebrand, country manager of Neurim Pharmaceuticals Switzerland, a neuroscience specialty company, discusses the launch of their lead product Circadin, the only IP-protected product providing a prolonged release formulation of melatonin for insomnia. Neurim Pharmaceuticals is an Israeli company focused on CNS, with a second office in Switzerland. Could you…
Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…
Pharma Corina Croitoru of Gedeon Richter Slovakia discusses GR’s footprint in the country, the affiliate’s main growth drivers, the importance of women’s health, and the intricacies of market access. Gedeon Richter’s affiliate in Slovakia was established back in 1996 and you yourself have been country manager for the past couple of…
Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…
Health Alberto Hechanova, president of the Drugstore Association of the Philippines (DSAP), discusses the competitive landscape of the country, highlighting the main challenges and opportunities for independent drugstores. In addition, he explains why being a member of the association can impact business success. Mr Hechanova, could you please introduce yourself and…
Pharma The Singapore Association of Pharmaceutical Industries’ (SAPI) recently appointed president, Ti Hwei How highlights several unique attributes that distinguish Singapore’s renowned healthcare system from others around the world, while delineating three potential avenues for expanding patient access to innovative medicines. To begin, Ti Hwei, how would you characterize the specificities…
See our Cookie Privacy Policy Here
